<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748163</url>
  </required_header>
  <id_info>
    <org_study_id>2007LS098</org_study_id>
    <secondary_id>0802M26201</secondary_id>
    <secondary_id>ABX080</secondary_id>
    <secondary_id>GA6181W</secondary_id>
    <nct_id>NCT00748163</nct_id>
  </id_info>
  <brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Sunitinib may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.&#xD;
      Giving paclitaxel albumin-stabilized nanoparticle formulation together with sunitinib may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving paclitaxel albumin-stabilized&#xD;
      nanoparticle formulation together with sunitinib works as first-line therapy in treating&#xD;
      patients with stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the tumor response rate in patients with stage IV non-small cell lung&#xD;
           cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib&#xD;
           malate as first-line therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the time to objective tumor response and duration of response in responding&#xD;
           patients.&#xD;
&#xD;
        -  To determine the time to treatment failure and overall survival of these patients.&#xD;
&#xD;
        -  To characterize the toxicities of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30&#xD;
      minutes on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days&#xD;
      1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 8 weeks until disease&#xD;
      progression and then every 3 months for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study has been abandoned for lack of available funding.&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 2008</start_date>
  <completion_date type="Anticipated">August 2008</completion_date>
  <primary_completion_date type="Anticipated">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to objective tumor response as assessed by RECIST criteria</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and adverse events as assessed by NCI CTCAE v3.0</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Stage IV Non-Small Cell Lung Cancer Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib malate as first-line therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
    <arm_group_label>Stage IV Non-Small Cell Lung Cancer Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <arm_group_label>Stage IV Non-Small Cell Lung Cancer Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
          -  At least 1 measurable lesion as defined by modified RECIST criteria&#xD;
&#xD;
          -  No symptomatic or untreated brain metastases&#xD;
&#xD;
               -  Prior brain metastases allowed provided the CNS disease has been treated and is&#xD;
                  considered stable and the patient has recovered from the acute toxic effects of&#xD;
                  the treatment prior to study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  WBC ≥ 3.0 x 10^9/L&#xD;
&#xD;
          -  ANC ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN if liver has tumor&#xD;
             involvement)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  LVEF ≥ 40% by MUGA&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Congestive heart failure, myocardial infarction, or coronary artery bypass graft&#xD;
             within the past 12 months&#xD;
&#xD;
          -  Ongoing severe or unstable angina&#xD;
&#xD;
          -  Unstable arrhythmia requiring medication&#xD;
&#xD;
          -  Sensory neuropathy ≥ grade 2 (according to NCI CTCAE v3.0)&#xD;
&#xD;
          -  Known hypersensitivity to any of the agents used in this study&#xD;
&#xD;
          -  Serious medical or psychiatric illness that, in the opinion of the enrolling&#xD;
             investigator, is likely to interfere with study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior systemic therapy for NSCLC&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  More than 7 days since prior and no concurrent potent CYP3A4 inhibitors, including any&#xD;
             of the following:&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Delavirdine&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Atazanavir&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
          -  More than 12 days since prior and no concurrent potent CYP3A4 inducers, including any&#xD;
             of the following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  St. John's wort&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Tipranavir&#xD;
&#xD;
          -  No concurrent treatment with a drug having proarrhythmic potential, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Terfenadine&#xD;
&#xD;
               -  Quinidine&#xD;
&#xD;
               -  Procainamide&#xD;
&#xD;
               -  Disopyramide&#xD;
&#xD;
               -  Sotalol&#xD;
&#xD;
               -  Probucol&#xD;
&#xD;
               -  Bepridil&#xD;
&#xD;
               -  Haloperidol&#xD;
&#xD;
               -  Risperidone&#xD;
&#xD;
               -  Indapamide&#xD;
&#xD;
               -  Flecainide&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arkadiusz Dudek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

